Effects of fingolimod in relapsing-remitting multiple sclerosis

Per Soelberg Sorensen

doi:10.1016/s1474-4422(14)70067-5

Effects of fingolimod in relapsing-remitting multiple sclerosis

Department of Clinical Medicine

6 Citations (Scopus)

Original language	English
Journal	Lancet Neurology
Volume	13
Issue number	6
Pages (from-to)	526-527
Number of pages	2
ISSN	1474-4422
DOIs	https://doi.org/10.1016/s1474-4422(14)70067-5
Publication status	Published - Jun 2014

Keywords

Clinical Trials as Topic
Humans
Immunosuppressive Agents
Multiple Sclerosis, Relapsing-Remitting
Propylene Glycols
Sphingosine
Treatment Outcome

Access to Document

10.1016/s1474-4422(14)70067-5

Cite this

@article{1d3b32aa6089455aa2588eceb6e15588,

title = "Effects of fingolimod in relapsing-remitting multiple sclerosis",

keywords = "Clinical Trials as Topic, Humans, Immunosuppressive Agents, Multiple Sclerosis, Relapsing-Remitting, Propylene Glycols, Sphingosine, Treatment Outcome",

author = "Sorensen, {Per Soelberg}",

year = "2014",

month = jun,

doi = "10.1016/s1474-4422(14)70067-5",

language = "English",

volume = "13",

pages = "526--527",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "TheLancet Publishing Group",

number = "6",

}

TY - JOUR

T1 - Effects of fingolimod in relapsing-remitting multiple sclerosis

AU - Sorensen, Per Soelberg

PY - 2014/6

Y1 - 2014/6

KW - Clinical Trials as Topic

KW - Humans

KW - Immunosuppressive Agents

KW - Multiple Sclerosis, Relapsing-Remitting

KW - Propylene Glycols

KW - Sphingosine

KW - Treatment Outcome

U2 - 10.1016/s1474-4422(14)70067-5

DO - 10.1016/s1474-4422(14)70067-5

M3 - Comment/debate

C2 - 24685277

SN - 1474-4422

VL - 13

SP - 526

EP - 527

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 6

ER -